Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors
Univ Athens, Dept Pathophysiol, Endocrine Unit.
Royal Free Hosp, Neuroendocrine Tumour Unit.
Royal Free Hosp, Neuroendocrine Tumour Unit.
Univ Genoa, IRCCS AOU San Martino IST, Dept Internal Med & Med Specialties DiMI, Endocrinol Unit, CEBR.
Show others and affiliations
2017 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 105, no 3, p. 245-254Article in journal (Refereed) Published
Abstract [en]

Neuroendocrine tumors of the small intestine are the most common causes of the carcinoid syndrome. Carcinoid heart disease occurs in more than half of the patients with the carcinoid syndrome. Patients with carcinoid heart disease who need to undergo surgery should also undergo preoperative evaluation by an expert cardiologist. Treatment with longacting somatostatin analogs aims at controlling the excessive hormonal output and symptoms related to the carcinoid syndrome and at preventing a carcinoid crisis during interventions. Patients with a gastrinoma require pre- and postoperative treatment with high doses of proton pump inhibitors. Patients with a glucagonoma require somatostatin analog treatment and nutritional supplementation. Patients with a VIPoma also require somatostatin analog treatment and intravenous fluid and electrolyte therapy. Insulinoma patients generally require intravenous glucose infusion prior to operation. In patients with localized operable insulinoma, somatostatin analog infusion should only be considered after the effect of this therapy has been electively studied.

Place, publisher, year, edition, pages
2017. Vol. 105, no 3, p. 245-254
Keywords [en]
Neuroendocrine tumor, Carcinoid, Carcinoid syndrome, Carcinoid heart disease
National Category
Neurosciences Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:uu:diva-336662DOI: 10.1159/000461583ISI: 000411501200005PubMedID: 28253514OAI: oai:DiVA.org:uu-336662DiVA, id: diva2:1170792
Available from: 2018-01-04 Created: 2018-01-04 Last updated: 2018-01-13Bibliographically approved

Open Access in DiVA

fulltext(132 kB)36 downloads
File information
File name FULLTEXT01.pdfFile size 132 kBChecksum SHA-512
7a3ca81c4810ca07e56f2bba5b0e9c2739fa70b0764b55de960cf29d8d8bdcfeb113f222aec77826d337f20f4c0ef9b1b5e16184160c67423df2dd6023555184
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Tiensuu Janson, Eva
By organisation
Endocrin Oncology
In the same journal
Neuroendocrinology
NeurosciencesEndocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 36 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 47 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf